Shares in Value Logo
Product Review Img Vertical

Date : 14/04/2021

Pharmaxis Shares Jump On Announcement of Distribution Rights

Pharmaxis is a Sydney based pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function tests. It operates through the following segments: Mannitol Business and New Drug Development. The Mannitol Business segment covers the clinical development, manufacture and sale of Bronchitol and Aridol globally. The New Drug Development segment encompasses the drug discovery and early stage clinical development of the group’s new drug candidates. Pharmaxis is in its clinical drug development stage and is targeting fibrosis and cancer.

Pharmaxis (ASX:PXS) Shares Price Jumped 9% on Sale of Distribution Rights

This morning, Pharmaxis announced the sale of the distribution rights in Russia for its cystic fibrosis product Bronchitol. In addition to the A$2m sale price, Pharmaxis has secured ongoing annual savings of A$1m in marketing and regulatory expenses. Pharmaxis will continue to manufacture and export Bronchitol to Russia from its factory in Sydney that also supplies the US, European and Australian markets.

In addition to the distribution rights, Pharmaxis also announced a capital raising today via a placement offer. The placement is aimed at institutional investors to raise approximately A$4.4m at A$0.08 per share. The funds raised will be used to strengthen the firm’s balance sheet as the Company conducts a study in myelofibrosis with its lead drug PXS‐5505, and a phase 1c study in patients with problematic skin scarring with its topical drug PXS‐6302.

Post the fundraise, Pharmaxis will have about A$20 million in cash in the bank. PXS shares closed $0.084 today after surging over 6% on the back of these two major announcements.

Looking for top 5 ASX Stocks to invest right now?

Growth stocks are potentially one of the hardest to pick as there are a lot of factors that need to be considered – from industry tailwinds to the financial health of the individual stocks and a lot of little things in between them. Shares in the Value research team have picked their top 5 ASX stocks to buy in 2021. Click here to download the report for free.


Are You Looking To Buy The Best Stocks In 2024?

Stay on top of upcoming market trends! Whether you are an SMSF investor or a young investor with your portfolio, we cover a wide range of stocks across all sectors, including mining, financials, industrials, real estate, technology, health and biotech, etc. It will give you an edge to invest and trade ASX listed stocks across large, mid and small caps with an advantage.

Get stock tips with our Market Experts. We help self-directed investors and self-managed super funds (SMSF) make smarter investment decisions and get better returns. Fill in your details and download your free Report instantly for Top 3 Dividend Stocks to buy in 2024!


Top 5 ASX Stocks
to Buy for Capital Growth in 2024

Shares In Value - Top 5 ASX Stocks to Buy - Cover 2024
The hardest part to finding growth stocks is having an ability to understand the finer details of these companies from their valuations through to first mover advantage and having key factors on hand to make informed investment decisions.

Our experts take the guesswork out.
ASX insight Stocks Landing

Download Your Free Report

By downloading this report, you agree to our terms and conditions and privacy policy

Scroll to Top


By submitting this form, I agree to the TERMS AND CONDITIONS and PRIVATE POLICY

Income Stocks - Blogs

Please fill in your details to download the free dividend shares report.

By downloading this report, you agree to our terms and conditions and privacy policy

Just 10 Seconds Away From Your Free Report!
Income Stocks - Popup Blog

Please fill in your details to download the free dividend shares report.

By clicking 'Download Report', I accept the Privacy Policy and Member Terms & Conditions.

We will send your report instantly. Please put your correct email address and phone number.